Boston, MA, San Francisco, CA, Tokyo, Japan and Cologne, Germany April 17th, 2017—Locust Walk, a leading life sciences transaction advisory firm, is pleased to announce that it has appointed Hunt Henrie as a Managing Director. Based in the firm’s Boston, MA office, Mr. Henrie will be responsible for leading the firm’s growing Medical Technology practice.
“Both Chris Ehrlich, Managing Director of Locust Walk, and I have known Hunt for more than a decade and are extremely impressed by his approach, track record and fit with Locust Walk’s team-based style”, commented Geoff Meyerson, Managing Partner and Co-Founder of Locust Walk. “We are excited to have Hunt join us as we look to build a premier medical technology transactions practice within Locust Walk.”
Hunt brings to Locust Walk over 30 years of broad-based global financial, investment banking, private equity and corporate operating experience, of which the last 26 have been in healthcare. Hunt has raised more than $6 billion in capital in support of M&A, principal investing and IPO activities, and been involved in over $5 billion of strategic transactions. He has spent 15 years at Ferghana Partners where he has been responsible for the firm’s Private Placement and Medical Technology practice. Hunt began his career with Chase Manhattan and was a founding member of Chase’s European Mezzanine Capital Group which later became Chase Capital Partners Europe. Hunt spent six years operating in the biomedical industry with Instrumentation Laboratory where he was Managing Director for Worldwide Corporate Finance and CFO of IL’s US subsidiary. He also served as CFO and SVP of Business Development for digital health firm NorthPoint Domain.
Hunt Henrie, Managing Director, said, “I am excited to join Locust Walk as the firm expands its presence beyond the global biopharmaceutical sector to serve companies in the medical technology industry. We intend to leverage the firm’s excellent reputation and track record to achieve success for our medical technology clients”.
Locust Walk also announced the appointment of Stephen (Steve) N. Oesterle, M.D., to its Advisory Board. Dr. Oesterle currently serves as a consultant to several private equity groups and numerous private and public operating companies in the healthcare industry. He is currently an independent board director at Baxter International. Dr. Oesterle served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. He also held prior roles as associate professor of medicine and director of Invasive Cardiology Services at Harvard Medical School-affiliated Massachusetts General Hospital, Stanford University Medical Center and Georgetown University Medical Center. Dr. Oesterle received his bachelor’s degree, summa cum laude, from Harvard University; his medical degree, cum laude, from Yale University School of Medicine; and conducted his residency at Massachusetts General Hospital. He completed a post-doctoral fellowship in cardiology at Stanford University Medical Center.
Dr. Oesterle said, “Locust Walk has proven itself in the biopharmaceutical arena and is now making a logical move to serve companies in the medical technology sector with high quality advice. I have known and worked with Hunt since 2000, and am pleased to join the Locust Walk Advisory Board to support Hunt’s and the firm’s efforts to create a leading Medical Technology advisory practice.”
About Locust Walk
Locust Walk is a leading life sciences transaction advisory firm focused on biopharmaceutical and medical technology companies. Our team of experienced professionals fuels the growth of promising companies at every stage by connecting the right products, the right partners and the most attractive sources of capital – driving innovation for growth and transformative results.
Locust Walk was founded in 2008 and currently has offices in Boston, San Francisco, Tokyo and Cologne. Over the past two years, Locust Walk has completed 21 transactions for its clients around the world, with total of 35 transactions across a variety of deal types, stages of development and therapeutic areas. For further information, please visit www.locustwalk.com